1
|
Jafari MJ, Rahimi A, Omidi L, Behzadi MH, Rajabi MH. Occupational Exposure and Health Impairments of Formaldehyde on Employees of a Wood Industry. Health Promot Perspect 2016; 5:296-303. [PMID: 26933649 PMCID: PMC4772800 DOI: 10.15171/hpp.2015.035] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2015] [Accepted: 10/04/2015] [Indexed: 12/23/2022] Open
Abstract
Background: Occupational exposure to formaldehyde may decrease white blood cell counts and change blood concentration. In this study, the influences of occupational exposure to formaldehyde on the number of white blood cells and blood concentrations were studied. Methods: This case-control study was conducted in June of 2012 at North Wood Factory, Golestan Province, Iran. The US-NIOSH method No. 2541 was used to determine the occupational exposure of 30 workers of the production line (case group) and 30 administrative staffs (control group) to formaldehyde. The number of white blood cells and blood concentration were determined using the normal blood count method and related indices. Demographic features as well as the symptoms of being exposed to formaldehyde were collected using a standard questionnaire. Results: The occupational exposure of case group ranged from 0.50 ppm to 1.52 ppm. The prevalence of all studied symptoms from formaldehyde exposure in workers (2<median<5; range 1 to 5) was significantly different (P<0.001) towards the administrative staffs (median 1; range 1 to 4). The number of white blood cells in production line workers was not significantly different from those in administrative staff. The average blood concentration in the case group was significantly different from the control group (mean difference= 0.9 [95% CI: 0.40-1.39];P=0.007). Conclusion: Occupational exposure to formaldehyde changed the blood concentration of the studied workers but did not change the number of their white blood cells.
Collapse
Affiliation(s)
- Mohammad Javad Jafari
- Occupational Health Engineering Department, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Abolfazl Rahimi
- Department of Environment and Energy, Science and Research Branch, Islamic Azad University, Tehran, Iran
| | - Leila Omidi
- Occupational Health Engineering Department, Tehran University of Medical Sciences, Tehran, Iran
| | - Mohammad Hassan Behzadi
- Department of Statistics, Science and Research Branch, Islamic Azad University, Tehran, Iran
| | | |
Collapse
|
2
|
Wang ES, Lyons RM, Larson RA, Gandhi S, Liu D, Matei C, Scott B, Hu K, Yang AS. A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. J Hematol Oncol 2012. [PMID: 23190430 PMCID: PMC3520696 DOI: 10.1186/1756-8722-5-71] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Background Lenalidomide treatment in myelodysplastic syndrome (MDS) may lead to thrombocytopenia and dose reductions/delays. This study evaluated the safety and tolerability of the thrombopoietin mimetic romiplostim and its effects on the incidence of clinically significant thrombocytopenic events (CSTEs) in lower risk MDS patients receiving lenalidomide. Methods Patients were assigned to weekly placebo (n = 12) or romiplostim 500 μg (n = 14) or 750 μg (n = 13) for four 28-day lenalidomide cycles. Results The treatment groups were generally similar with respect to baseline disease characteristics. Del(5q) abnormalities were noted in 1 (8%) patient in the placebo group, 3 (21%) in the romiplostim 500 μg group, and two (15%) in the 750 μg group. CSTEs were noted in 8 (67%) patients in the placebo group, 4 (29%) in the romiplostim 500 μg group, and 8 (62%) in the romiplostim 750 μg group. Throughout the study, median platelet counts trended lower in placebo-treated than in romiplostim-treated patients. Thrombocytopenia-related adjustments in lenalidomide occurred in 6 (50%) patients in the placebo group, 5 (36%) in the romiplostim 500 μg group, and 2 (15%) in the 750 μg group. Although the percentages of patients who received platelet transfusions were similar across treatment groups, there was a trend toward lower numbers of transfusions in both romiplostim groups during each treatment cycle. There were two serious treatment-related adverse events during the treatment period (cerebrovascular accident, placebo; worsening thrombocytopenia, romiplostim 500 μg). Two patients (romiplostim 500 and 750 μg, respectively) had an increase in bone marrow blasts to >20% during treatment, but had no post-treatment biopsy to confirm or exclude the diagnosis of progression to AML. Conclusions These data suggest that romiplostim administered to MDS patients during lenalidomide treatment may decrease the frequency of dose reductions/delays due to thrombocytopenia. Additional study is needed to confirm the results of this preliminary trial. Trial registration ClinicalTrials.gov NCT00418665
Collapse
Affiliation(s)
- Eunice S Wang
- Leukemia Service, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Important genes in the pathogenesis of 5q- syndrome and their connection with ribosomal stress and the innate immune system pathway. LEUKEMIA RESEARCH AND TREATMENT 2012; 2012:179402. [PMID: 23213547 PMCID: PMC3504201 DOI: 10.1155/2012/179402] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/25/2011] [Revised: 11/06/2011] [Accepted: 11/14/2011] [Indexed: 01/10/2023]
Abstract
Myelodysplastic syndrome (MDS) with interstitial deletion of a segment of the long arm of chromosome 5q [del(5q)] is characterized by bone marrow erythroid hyperplasia, atypical megakaryocytes, thrombocythemia, refractory anemia, and low risk of progression to acute myeloid leukemia (AML) compared with other types of MDS. The long arm of chromosome 5 contains two distinct commonly deleted regions (CDRs). The more distal CDR lies in 5q33.1 and contains 40 protein-coding genes and genes coding microRNAs (miR-143, miR-145). In 5q-syndrome one allele is deleted that accounts for haploinsufficiency of these genes. The mechanism of erythroid failure appears to involve the decreased expression of the ribosomal protein S14 (RPS14) gene and the upregulation of the p53 pathway by ribosomal stress. Friend leukemia virus integration 1 (Fli1) is one of the target genes of miR145. Increased Fli1 expression enables effective megakaryopoiesis in 5q-syndrome.
Collapse
|
4
|
|
5
|
Abstract
Patients with lower risk myelodysplastic syndrome (MDS) are those with low or intermediate-1 (INT-1) risk disease by the International Prognostic Scoring System (IPSS) index. Traditionally this has been a subset of patients where the philosophy of therapy has focused on improving transfusion needs. This is the result of the perception that the natural course of patients with lower risk disease is benign and the correct assumption that forms of therapy associated with early induction mortality cannot be justified. Over the last 5 years, we have witnessed significant improvements in our understanding of the natural history and therapy of patients with lower risk MDS. That said, it is not clear that any of these approaches improves survival. In this chapter, I will try to integrate information provided in other articles presented in this issue of Seminars in Oncology with new information regarding the heterogeneity of the natural history of patients with lower risk MDS and propose a framework for future research initiatives for this group of patients.
Collapse
|
6
|
Abstract
The 5q- syndrome is a unique subtype of myelodysplastic syndromes typified by a relatively indolent course and responsiveness to lenalidomide. Here, we review the salient biologic features of this disease. Hemizygous deletion of a segment of chromosome 5q is believed to be the disease-initiating event. Recent molecular techniques have isolated the common deleted region and characterized key candidate genes contributing to the disease phenotype. Gene-specific RNA interference strategies revealed that haplo-insufficiency for the RPS14 gene, which encodes a ribosomal protein, is a critical effector of the p53-dependent erythroid hypoplasia and apoptotic loss of erythroid precursors. Disease-specific sensitivity to lenalidomide results from the drug's inhibitory effect on two haplodeficient phosphatases, PP2Acα and CDC25c, which are coregulators of the G(2)/M checkpoint. Hyperphosphorylation of MDM2, as a result of inhibition of PP2A phosphatase activity, stabilizes MDM2, permitting p53 degradation and transition to G(2) arrest and clonal suppression. With the emerging data elucidating the pathogenesis of the 5q- syndrome and the success of clinical trials, a cohesive story connecting the biology and pharmacology associated with this subtype of myelodysplastic syndromes has emerged.
Collapse
Affiliation(s)
- Eric Padron
- Hematologic Malignancy Division, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
| | | | | |
Collapse
|
7
|
Abstract
The myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders characterised by impaired peripheral blood cell production due to bone marrow dysplasia affecting one or more of the major myeloid cell lines. MDS are one of five major categories of myeloid neoplasms according to the World Health Organization (WHO) classification system for haematological cancers. Given their cytological and cytogenetic heterogeneity, these diseases probably constitute a group of molecularly distinct entities with variable degrees of ineffective haematopoiesis and susceptibility to leukaemic transformation. Recent studies provide some insights into the physiopathology of MDS. In the early stages, one mechanism contributing to hypercellular marrow and peripheral blood cytopenia is a significant increase in programmed cell death (apoptosis) in haematopoietic cells. Furthermore, altered responses in relation to cytokines, the immune system and bone marrow stroma also contribute to the disease phenotype. Deletions of chromosome 5q31-q32 are the most common recurring cytogenetic abnormalities detected in MDS. The 5q- syndrome is a new entity recognised in the WHO classification since 2001 and is associated with a good prognosis. Haploinsufficiency of multiple genes mapping to the common deleted region at 5q31-32 may contribute to the pathogenesis of 5q- syndrome and other MDS with 5q- deletion. Many studies have demonstrated that altered DNA methylation and histone acetylation can alter gene transcription. Abnormal methylation of transcription promoter sites is universal in patients with MDS, and the number of involved loci is increased in high-risk disease and secondary leukaemias. A better understanding of the pathogenesis of MDS can contribute to the development of new treatments such as hypomethylating drugs, immunomodulatory agents such as lenalidomide, and immunosuppressive drugs aimed at reversing the specific alteration that results in improvement in patients with MDS.
Collapse
Affiliation(s)
- Mar Tormo
- Hematology and Oncology Service, Valencia University Clinic Hospital, Valencia, Spain.
| | | | | |
Collapse
|
8
|
Three rearrangements of chromosome 5 in a patient with myelodysplastic syndrome: an atypical deletion 5q, a complex intrachromosomal rearrangement of chromosome 5, and a paracentric inversion of chromosome 5. ACTA ACUST UNITED AC 2010; 203:303-8. [DOI: 10.1016/j.cancergencyto.2010.07.129] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2010] [Revised: 07/12/2010] [Accepted: 07/18/2010] [Indexed: 11/13/2022]
|
9
|
Wong KF, Yu PH, Wong WS. Essential thrombocythemia with deleted 5q – a genetic and morphologic hybrid? ACTA ACUST UNITED AC 2010; 201:39-41. [DOI: 10.1016/j.cancergencyto.2010.04.019] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2010] [Revised: 04/13/2010] [Accepted: 04/21/2010] [Indexed: 11/28/2022]
|
10
|
Herry A, Douet-Guilbert N, Morel F, Le Bris MJ, Guéganic N, Berthou C, De Braekeleer M. Isochromosome 5p and related anomalies: a novel recurrent chromosome abnormality in myeloid disorders. ACTA ACUST UNITED AC 2010; 200:134-9. [PMID: 20620596 DOI: 10.1016/j.cancergencyto.2010.04.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2010] [Revised: 03/17/2010] [Accepted: 04/07/2010] [Indexed: 12/14/2022]
Abstract
Loss of material from chromosome arm 5q is a common finding in patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Fluorescence in situ hybridization with a panel of different types of probes, used as a complement to conventional cytogenetics, revealed that 7 of 148 patients (4.7%) with abnormalities of chromosome 5 had an i(5)(p10), an idic(5)(q11), or a structurally rearranged i(5)(p10). Three patients had MDS and four had AML. Six of the patients were female, and one was male; age at diagnosis ranged from 56 to 85 years. All patients but one had a complex karyotype. Isochromosome of the short arm of chromosome 5 and its related abnormalities such as idic(5)(q11) and structurally rearranged i(5)(p10) are rare but recurrent abnormalities; their identification requires a combination of conventional and molecular cytogenetic techniques. The biological and clinical significance cannot yet be assessed, not only because too few cases have been described but also because these abnormalities are usually part of a complex karyotype.
Collapse
Affiliation(s)
- Angèle Herry
- Laboratory of Histology, Embryology, and Cytogenetics, Faculty of Medicine and Health Sciences, Université de Bretagne Occidentale, 22 avenue Camille Desmoulins, Brest cedex 3l, France
| | | | | | | | | | | | | |
Collapse
|
11
|
Oliva EN, Cuzzola M, Nobile F, Ronco F, D'Errigo MG, Laganà C, Morabito F, Galimberti S, Cortelezzi A, Aloe Spiriti MA, Specchia G, Poloni A, Breccia M, Ghio R, Finelli C, Iacopino P, Alimena G, Latagliata R. Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion. Eur J Haematol 2010; 85:231-5. [PMID: 20491881 DOI: 10.1111/j.1600-0609.2010.01473.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
BACKGROUND Haploinsufficiency of the ribosomal protein S14 RPS14 gene, located in the common deleted region of chromosome 5q, is a potential causal factor of 5q- syndrome. Lenalidomide elicits high response rates and morphological improvements in myelodysplastic syndrome (MDS) patients with chromosome 5q deletion [del(5q)]. METHODS To further evaluate the role of RPS14, its transcription was tested in bone marrow cells from 17 patients with International Prognostic Scoring System defined Low- or Intermediate-1-risk MDS with del(5q) as a single or additional cytogenetic abnormality receiving treatment with lenalidomide. RESULTS After 12 wk of lenalidomide treatment, erythroid responses were observed in all cases with an increase in hemoglobin levels of 2.7 +/- 2.5 g/dL (up to a mean 11.8 +/- 1.9 g/dL; P = 0.001). Before treatment, RPS14 expression levels were under-expressed in 15 patients with respect to normal controls. After 12 wk of lenalidomide treatment, all patients had an erythroid response. There was a significant increase in median RPS14 expression from baseline 0.01 (IQR 0.05-0.31) to 12 wk 204.71-fold (2.86-446.32; P < 0.0001). CONCLUSIONS These observations in the patient setting support the importance of RPS14 in the pathogenesis of MDS with del(5q).
Collapse
Affiliation(s)
- Esther N Oliva
- Hematology Unit, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Lin P, Luthra R, Nussenzveig RH, Medeiros LJ. JAK2 V617F mutation is uncommon in patients with the 3q21q26 syndrome. Hum Pathol 2010; 41:758-62. [DOI: 10.1016/j.humpath.2009.11.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/23/2009] [Revised: 11/02/2009] [Accepted: 11/04/2009] [Indexed: 10/19/2022]
|
13
|
High-resolution oligonucleotide array comparative genomic hybridization study and methylation status of the RPS14 gene in de novo myelodysplastic syndromes. ACTA ACUST UNITED AC 2010; 197:166-73. [PMID: 20193850 DOI: 10.1016/j.cancergencyto.2009.11.012] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2009] [Revised: 10/23/2009] [Accepted: 11/19/2009] [Indexed: 11/22/2022]
Abstract
In myelodysplastic syndromes (MDS), close to one half of patients do not have any visible karyotypic change. In order to study submicroscopic genomic alterations, we applied high-resolution array comparative genomic hybridization techniques (aCGH) in 37 patients with de novo MDS. Furthermore, we studied the methylation status of the RPS14 gene in 5q deletion (5q21.3q33.1) in 24 patients. In all, 21 of the 37 patients (57%) had copy number alterations. The most frequent copy number losses with minimal common overlapping areas were 5q21.3q33.1 (21%) and 7q22.1q33 (19%); the most frequent copy number gain was gain of the whole chromosome 8 (8%). Recurrent, but less frequent copy number losses were detected in two cases each: 11q14.1q22.1, 11q22.3q24.2, 12p12.2p13.31, 17p13.2, 18q12.1q12.2, 18q12.3q21.3, 18q21.2qter, and 20q11.23q12; the gains 8p23.2pter, 8p22p23.1, 8p12p21.1, and 8p11.21q21.2 were similarly found in two cases each. No homozygous losses or amplifications were observed. The RPS14 gene was not methylated in any of the patients.
Collapse
|
14
|
Wong KF, Wong WS, Siu LLP, Lau TC, Chan NP. JAK2 V617F mutation is associated with 5q- syndrome in Chinese. Leuk Lymphoma 2010; 50:1333-5. [PMID: 19562618 DOI: 10.1080/10428190903060103] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
JAK2 V617F mutation is mostly seen in BCR-ABLI negative myeloproliferative neoplasms. Among other myeloid neoplasms, it occurs with remarkably high frequency in refractory anemia with ring sideroblasts associated with marked thrombocytosis, a group of myeloid neoplasms with both dysplastic and proliferative features. It has also been reported in occasional cases of myelodysplastic syndrome with isolated del(5q), often with a diagnosis of refractory cytopenia with multilineage dysplasia. We performed a retrospective analysis of JAK2 V617F mutation in Chinese patients with myeloid neoplasms and isolated del(5q), and were able to demonstrate the frequent occurrence of JAK2 V617F mutation in 5q- syndrome.
Collapse
Affiliation(s)
- K F Wong
- Department of Pathology, Queen Elizabeth Hospital, Hong Kong SAR, China.
| | | | | | | | | |
Collapse
|
15
|
[Myelodysplastic syndromes]. Internist (Berl) 2010; 51:169-82; quiz 183-4. [PMID: 20082063 DOI: 10.1007/s00108-009-2552-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
A heterogeneous group of acquired clonal bone marrow diseases has been captured under the term of myelodysplastic syndromes (MDS) that occur predominantly at higher age and are characterized by peripheral cytopenias despite normal or increased cellularity of the bone marrow. The slowly evolving process of neoplastic transformation explains the clinical, morphological and prognostic heterogeneity which is not sufficiently addressed even in current classification systems. In the last decade, considerable progress has been made in dissecting the pathobiology of these complex disorders. Therapeutic measures have to consider the prognosis of MDS as well as individual factors of the patient. Whereas the early stages are treated with supportive care, iron chelators, hematopoietic growth factors and immunomodulatory agents, more advanced cases require the use of demethylating agents and cytotoxic chemotherapy with or without stem cell support. Allogeneic stem cell transplantation remains the only curative option in MDS.
Collapse
|
16
|
Zhang L, Tang X, Rothman N, Vermeulen R, Ji Z, Shen M, Qiu C, Guo W, Liu S, Reiss B, Laura Beane F, Ge Y, Hubbard AE, Hua M, Blair A, Galvan N, Ruan X, Alter BP, Xin KX, Li S, Moore LE, Kim S, Xie Y, Hayes RB, Azuma M, Hauptmann M, Xiong J, Stewart P, Li L, Rappaport SM, Huang H, Fraumeni JF, Smith MT, Lan Q. Occupational exposure to formaldehyde, hematotoxicity, and leukemia-specific chromosome changes in cultured myeloid progenitor cells. Cancer Epidemiol Biomarkers Prev 2010; 19:80-8. [PMID: 20056626 PMCID: PMC2974570 DOI: 10.1158/1055-9965.epi-09-0762] [Citation(s) in RCA: 124] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
There are concerns about the health effects of formaldehyde exposure, including carcinogenicity, in light of elevated indoor air levels in new homes and occupational exposures experienced by workers in health care, embalming, manufacturing, and other industries. Epidemiologic studies suggest that formaldehyde exposure is associated with an increased risk of leukemia. However, the biological plausibility of these findings has been questioned because limited information is available on the ability of formaldehyde to disrupt hematopoietic function. Our objective was to determine if formaldehyde exposure disrupts hematopoietic function and produces leukemia-related chromosome changes in exposed humans. We examined the ability of formaldehyde to disrupt hematopoiesis in a study of 94 workers in China (43 exposed to formaldehyde and 51 frequency-matched controls) by measuring complete blood counts and peripheral stem/progenitor cell colony formation. Further, myeloid progenitor cells, the target for leukemogenesis, were cultured from the workers to quantify the level of leukemia-specific chromosome changes, including monosomy 7 and trisomy 8, in metaphase spreads of these cells. Among exposed workers, peripheral blood cell counts were significantly lowered in a manner consistent with toxic effects on the bone marrow and leukemia-specific chromosome changes were significantly elevated in myeloid blood progenitor cells. These findings suggest that formaldehyde exposure can have an adverse effect on the hematopoietic system and that leukemia induction by formaldehyde is biologically plausible, which heightens concerns about its leukemogenic potential from occupational and environmental exposures.
Collapse
Affiliation(s)
- Luoping Zhang
- School of Public Health, University of California, Berkeley, CA 94720
| | | | - Nathaniel Rothman
- Division of Cancer Epidemiology and Genetics, NCI, NIH, DHHS, Bethesda, MD 20892
| | | | - Zhiying Ji
- School of Public Health, University of California, Berkeley, CA 94720
| | - Min Shen
- Division of Cancer Epidemiology and Genetics, NCI, NIH, DHHS, Bethesda, MD 20892
| | - Chuangyi Qiu
- Guangdong Poisoning Control Center, Guangzhou, China
| | - Weihong Guo
- School of Public Health, University of California, Berkeley, CA 94720
| | | | | | - Freeman Laura Beane
- Division of Cancer Epidemiology and Genetics, NCI, NIH, DHHS, Bethesda, MD 20892
| | - Yichen Ge
- Guangdong Poisoning Control Center, Guangzhou, China
| | - Alan E. Hubbard
- School of Public Health, University of California, Berkeley, CA 94720
| | - Ming Hua
- Guangdong Poisoning Control Center, Guangzhou, China
| | - Aaron Blair
- Division of Cancer Epidemiology and Genetics, NCI, NIH, DHHS, Bethesda, MD 20892
| | - Noe Galvan
- School of Public Health, University of California, Berkeley, CA 94720
| | - Xiaolin Ruan
- Guangdong Poisoning Control Center, Guangzhou, China
| | - Blanche P. Alter
- Division of Cancer Epidemiology and Genetics, NCI, NIH, DHHS, Bethesda, MD 20892
| | - Kerry X. Xin
- School of Public Health, University of California, Berkeley, CA 94720
| | - Senhua Li
- Guangdong Poisoning Control Center, Guangzhou, China
| | - Lee E. Moore
- Division of Cancer Epidemiology and Genetics, NCI, NIH, DHHS, Bethesda, MD 20892
| | - Sungkyoon Kim
- School of Public Health, University of North Carolina, Chapel Hill, NC 27709
| | - Yuxuan Xie
- Guangdong Poisoning Control Center, Guangzhou, China
| | - Richard B. Hayes
- Division of Cancer Epidemiology and Genetics, NCI, NIH, DHHS, Bethesda, MD 20892
| | - Mariko Azuma
- School of Public Health, University of California, Berkeley, CA 94720
| | - Michael Hauptmann
- Division of Cancer Epidemiology and Genetics, NCI, NIH, DHHS, Bethesda, MD 20892
| | - Jun Xiong
- Dongguan Center for Disease Control and Prevention, Guangdong, China
| | - Patricia Stewart
- Division of Cancer Epidemiology and Genetics, NCI, NIH, DHHS, Bethesda, MD 20892
| | - Laiyu Li
- Guangdong Poisoning Control Center, Guangzhou, China
| | - Stephen M. Rappaport
- School of Public Health, University of California, Berkeley, CA 94720
- School of Public Health, University of North Carolina, Chapel Hill, NC 27709
| | - Hanlin Huang
- Guangdong Poisoning Control Center, Guangzhou, China
| | - Joseph F. Fraumeni
- Division of Cancer Epidemiology and Genetics, NCI, NIH, DHHS, Bethesda, MD 20892
| | - Martyn T. Smith
- School of Public Health, University of California, Berkeley, CA 94720
| | - Qing Lan
- Division of Cancer Epidemiology and Genetics, NCI, NIH, DHHS, Bethesda, MD 20892
| |
Collapse
|
17
|
Affiliation(s)
- Ayalew Tefferi
- Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
| | | |
Collapse
|
18
|
Ximeri M, Galanopoulos A, Klaus M, Parcharidou A, Giannikou K, Psyllaki M, Symeonidis A, Pappa V, Kartasis Z, Liapi D, Hatzimichael E, Kokoris S, Korkolopoulou P, Sambani C, Pontikoglou C, Papadaki HA. Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion. Haematologica 2009; 95:406-14. [PMID: 19773257 DOI: 10.3324/haematol.2009.010876] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND Lenalidomide improves erythropoiesis in patients with low/intermediate-1 risk myelodysplastic syndrome and interstitial deletion of the long arm of chromosome 5 [del(5q)]. The aim of this study was to explore the effect of lenalidomide treatment on the reserves and functional characteristics of bone marrow hematopoietic progenitor/precursor cells, bone marrow stromal cells and peripheral blood lymphocytes in patients with low/intermediate-1 risk myelodysplastic syndrome with del(5q). DESIGN AND METHODS We evaluated the number and clonogenic potential of bone marrow erythroid/myeloid/megakaryocytic progenitor cells using clonogenic assays, the apoptotic characteristics and adhesion molecule expression of CD34(+) cells by flow cytometry, the hematopoiesis-supporting capacity of bone marrow stromal cells using long-term bone marrow cultures and the number and activation status of peripheral blood lymphocytes in ten patients with low/intermediate-1 risk myelodysplastic syndrome with del(5q) receiving lenalidomide. RESULTS Compared to baseline, lenalidomide treatment significantly decreased the proportion of bone marrow CD34+ cells, increased the proportion of CD36(+)/GlycoA(+) and CD36(-)/GlycoA(+) erythroid cells and the percentage of apoptotic cells within these cell compartments. Treatment significantly improved the clonogenic potential of bone marrow erythroid, myeloid, megakaryocytic colony-forming cells and increased the proportion of CD34(+) cells expressing the adhesion molecules CD11a, CD49d, CD54, CXCR4 and the SLAM antigen CD48. The hematopoiesis-supporting capacity of bone marrow stroma improved significantly following treatment, as demonstrated by the number of colony-forming cells and the level of stromal-derived factor-1 alpha and intercellular adhesion molecule-1 in long-term bone marrow culture supernatants. Lenalidomide treatment also increased the proportion of activated peripheral blood T lymphocytes. CONCLUSIONS The beneficial effect of lenalidomide in patients with lower risk myelodysplastic syndrome with del(5q) is associated with significant increases in the proportion of bone marrow erythroid precursor cells and in the frequency of clonogenic progenitor cells, a substantial improvement in the hematopoiesis-supporting potential of bone marrow stroma and significant alterations in the adhesion profile of bone marrow CD34(+) cells.
Collapse
Affiliation(s)
- Maria Ximeri
- Department of Hematology, University of Crete School of Medicine, Heraklion, Crete, Greece
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
van der Walt J. Highlights of 2008 in bone marrow biopsy pathology. J Hematop 2009; 2:42-4. [PMID: 19669222 PMCID: PMC2713490 DOI: 10.1007/s12308-009-0025-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2009] [Accepted: 02/06/2009] [Indexed: 11/30/2022] Open
Affiliation(s)
- Jon van der Walt
- Department of Histopathology, St Thomas' Hospital, Westminster Bridge Road, London, SE1 7EH, UK,
| |
Collapse
|